NCT04306887View on ClinicalTrials.gov

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
Interventions
DRUG

TQ-B3101 capsule

Escalating doses starting at 200 mg bid.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY